title: Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study.
abstract: OBJECTIVE
  Transcranial magnetic stimulation was used to assess the effects of chronic levodopa and pergolide treatment on motor cortex excitability in Parkinson disease (PD).
  
  
  METHODS
  Motor thresholds, intracortical inhibition and facilitation were studied at baseline and after 6 and 12 months of therapy in 10 PD patients and compared to 7 age-matched controls.
  
  
  RESULTS
  At baseline, there was significantly less intracortical inhibition with only a slight reduction of intracortical facilitation in PD as compared to controls. Relative to pretreatment condition, levodopa restored intracortical inhibition for 12 months while pergolide did not. Intracortical facilitation was always within the normal range. Motor thresholds were unchanged in both groups of patients over 12 months. Clinically, levodopa and pergolide improved motor Unified Parkinson's disease rating scale (UPDRS) scores at 6 months but only levodopa maintained benefit at 12 months as compared to baseline.
  
  
  CONCLUSIONS
  Levodopa and pergolide differentially affected cortical inhibitory circuits at 12 months. The progressive deterioration of restored intracortical inhibition with pergolide may be due to the development of tolerance and down-regulation of dopamine receptors.
authors.affiliation: Department of Neurology, Bellaria Hospital, University of Bologna, Bologna, Italy. apstrafella@hotmail.com
authors.forename: A P
authors.initials: AP
authors.lastname: Strafella
authors.forename: F
authors.initials: F
authors.lastname: Valzania
authors.forename: S A
authors.initials: SA
authors.lastname: Nassetti
authors.forename: A
authors.initials: A
authors.lastname: Tropeani
authors.forename: A
authors.initials: A
authors.lastname: Bisulli
authors.forename: M
authors.initials: M
authors.lastname: Santangelo
authors.forename: C A
authors.initials: CA
authors.lastname: Tassinari
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004558:Electric Stimulation / Q000295:instrumentation; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008875:Middle Aged; D009044:Motor Cortex / Q000187:drug effects* / Q000503:physiopathology; D009433:Neural Inhibition / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010479:Pergolide / Q000008:administration & dosage*; D011930:Reaction Time / Q000187:drug effects; D012684:Sensory Thresholds / Q000187:drug effects; D012720:Severity of Illness Index; D050781:Transcranial Magnetic Stimulation
chemical_list: D010479:Pergolide; D007980:Levodopa